A telehealth company just launched a $49 knockoff of Novo Nordisk’s breakthrough weight-loss pill, prompting the pharmaceutical giant to threaten legal action over what it calls an “illegal” and dangerous counterfeit that puts American patients at risk.
Story Snapshot
- Hims & Hers Health released a compounded version of Novo Nordisk’s oral Wegovy pill at $49 per month, undercutting the branded drug by $100
- Novo Nordisk immediately threatened legal and regulatory action, calling the product an “unapproved, inauthentic, and untested knockoff” that endangers patient safety
- The confrontation caused major stock losses, with Novo Nordisk and competitor Eli Lilly shares dropping over 6%, while Hims & Hers stock also plummeted
- FDA previously warned Hims & Hers for deceptive advertising of weight-loss drug copies, raising questions about the company’s pattern of exploiting regulatory loopholes
Telehealth Giant Undercuts FDA-Approved Wegovy Launch
Hims & Hers Health announced the availability of a compounded oral semaglutide pill priced at $49 for the first month, directly competing with Novo Nordisk’s newly launched oral Wegovy.
The timing strikes at Novo’s most vulnerable moment, coming just one month after the Danish pharmaceutical company launched what became the fastest pharmaceutical rollout in history based on early prescription totals.
Novo Nordisk spokesperson Ambre James-Brown immediately condemned the move as “unlawfully mass-marketing an unapproved knockoff” that poses significant risks to patient safety.
Pattern of FDA Warnings Raises Regulatory Concerns
This confrontation represents the latest escalation in Hims & Hers’ controversial approach to weight-loss medications. The FDA previously issued warnings to the telehealth company specifically for deceptive advertising related to GLP-1 drug knockoffs.
Compounding pharmacies have exploited provisions under U.S. law Section 503A, which allows personalized doses during drug shortages, but continue mass-producing alternatives even after shortages end.
The practice undermines the rigorous FDA approval process that ensures drug safety and efficacy, creating a two-tiered system in which unapproved medications compete directly with thoroughly tested alternatives.
Market Impact Reveals Investor Alarm Over Copycat Threat
The financial fallout from Hims & Hers’ announcement demonstrated the serious threat compounding pharmacies pose to pharmaceutical innovation. Novo Nordisk and competitor Eli Lilly both saw shares plunge more than 6% following the news, erasing tens of billions in market value.
Hims & Hers stock also turned sharply negative despite its launch of what it positioned as an affordable alternative. Earlier in the week, Novo had already forecast declining 2026 sales growth, partly due to competition from copycat operations.
This highlights how these copycat operations undercut companies that invest billions in research, development, and safety testing to bring FDA-approved treatments to market.
Exclusive: Online telehealth company Hims and Hers Health will begin offering compounded copies of Novo Nordisk's new Wegovy pill at an introductory price of $49 per month, the company said, about $100 less than the brand name https://t.co/TLtqpU9w8N pic.twitter.com/8axXBoUXUt
— Reuters (@Reuters) February 5, 2026
Safety Questions Cloud Untested Formulation Claims
UBS analyst Michael Yee raised critical concerns about the compounded version’s legitimacy and safety profile. Hims & Hers claims its formulation differs from Novo’s FDA-approved pill by using alternative delivery methods to protect digestion, but Yee noted that these differences create “unclear” absorption rates and side effects.
Novo Nordisk emphasized that only its oral Wegovy has undergone the rigorous FDA approval process, warning that compounded versions risk containing impurities, untested additives, or incorrect doses.
While compounders currently hold approximately one million prescriptions compared to an estimated 100 million total GLP-1 prescriptions, the expansion into oral formulations opens a concerning new front in this battle.
Trump Administration Pricing Deal Highlights Legitimate Access Path
Novo Nordisk’s oral Wegovy pricing under a Trump administration deal demonstrates that legitimate pathways exist for affordable medication access without compromising safety standards.
The $49 Hims & Hers price undercuts Novo by $100, but this bargain-basement approach bypasses the accountability and quality controls that protect American consumers.
The confrontation intensifies the broader debate between maintaining FDA approval integrity versus allowing unregulated alternatives to be marketed as affordable options.
Novo has filed lawsuits against other compounders over injectable versions and appears prepared to expand legal action to protect its oral formulation, though no lawsuit has been filed yet against Hims & Hers as of the latest reports.
Sources:
BioPharma Dive – Hims & Hers launches compounded Wegovy copy, drawing Novo Nordisk legal threat
MedWatch – Novo Nordisk threatens legal action over Hims & Hers’ Wegovy copy
Pharmaphorum – Hims & Hers copies Novo Nordisk’s new Wegovy pill
